Table 2.

Examples of clinical trials involving Anti-TIM-3 bispecific

Identifier	Patients number	Recruitment status	Condition or disease	Target	Therapy protocol	Short description
NCT03708328 [182]	134	Active, not recruiting	Solid tumors Metastatic melanoma Non-small cell lung cancer (NSCLC) Small cell lung cancer (SCLC) Esophageal squamous cell carcinoma (ESCC)	TIM-3/PD-1	Drug: RO7121661	Phase I study of single agent RO7121661 (Anti-PD-1/Anti-TIM-3) consists of 2 parts: dose escalation and expansion
NCT04931654 [183]	81	Recruiting	Carcinoma, non-small-cell lung	TIM-3/PD-1	Drug: AZD7789	Phase I/IIa study of AZD7789 (Anti-PD-1/Anti-TIM-3) antibody in participants with advanced solid tumors
NCT05357651 [184]	100	Recruiting	Solid tumor Lymphoma	TIM-3/PD-1	Drug: LB1410	Phase I study of a bispecific antibody LB1410 (Anti-TIM-3/Anti-PD-1)
NCT05216835 [185]	180	Recruiting	Relapsed or refractory classical Hodgkin lymphoma	TIM-3/PD-1	Drug: AZD7789	Phase I/II study of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma. Study consists of 2 parts: Dose Escalation and Expansion
NCT03752177 [186]	12	Terminated	Solid tumor	PD-L1/TIM-3	Drug: LY3415244	Study of LY3415244 (Anti-PD-L1/Anti-TIM-3) bispecific antibody in patients with advanced solid tumors